E-LIB Suche - Ergebnisse für: Peyrin-Biroulet, L

1

P114 Role of NLRX1 Agonist NX-13 in Reducing Visceral Hyper..:

Verstockt, B ; Vermeire, S ; Peyrin-Biroulet, L...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i400-i401 , 2024

Link: https://doi.org/10.1093/..

2

DOP12 Efficacy and safety of obefazimod in UC patients at w..:

Vermeire, S ; Peyrin-Biroulet, L ; Danese, S...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i94-i95 , 2024

Link: https://doi.org/10.1093/..

3

P683 Economic impact of achieving mucosal healing on UC-rel..:

Peyrin-Biroulet, L ; Ungaro, R ; Rubin, D T...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1298-i1299 , 2024

Link: https://doi.org/10.1093/..

4

DOP11 Disease clearance after 16 weeks of treatment with ve..:

Jairath, V ; Zou, G ; Adsul, S...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i92-i93 , 2024

Link: https://doi.org/10.1093/..

5

P144 Modulation of Immunometabolism via NLRX1 or PLXDC2: No..:

Danese, S ; Colombel, J F ; Rieder, F...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i443-i445 , 2024

Link: https://doi.org/10.1093/..

6

P524 Etrasimod shows low risk of adverse events following c..:

Afzali, A ; Regueiro, M ; Yarur, A J...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1033-i1034 , 2024

Link: https://doi.org/10.1093/..

7

P752 Difficult-to-treat inflammatory bowel disease: effecti..:

Caron, B ; Habert, A ; Bonsack, O...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1405-i1405 , 2024

Link: https://doi.org/10.1093/..

8

P954 Cumulative response to guselkumab through week 24 of i..:

Rubin, D ; Sands, B ; Lichtenstein, G...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1732-i1733 , 2024

Link: https://doi.org/10.1093/..

9

P931 Burden of disease among Ulcerative Colitis patients wi..:

Armuzzi, A ; Danese, S ; Barreiro-de Acosta, M...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1694-i1696 , 2024

Link: https://doi.org/10.1093/..

10

P903 Persistence, efficacy and tolerance of subcutaneous In..:

Mathieu, N ; Heluwaert, F ; Riviere, P...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1655-i1655 , 2024

Link: https://doi.org/10.1093/..

11

P710 Prevalence, Characteristics and Management of Patients..:

Parigi, T L ; Massimino, L ; Carini, A...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1339-i1340 , 2024

Link: https://doi.org/10.1093/..

12

P679 Anti-TNF de-escalation following a treat-to-target str..:

Vuitton, L ; Poullenot, F ; Bouhnik, Y...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1290-i1290 , 2024

Link: https://doi.org/10.1093/..

13

P678 Long-term efficacy, safety and health-related quality ..:

Feagan Senior Scientific Officer, B G ; Matsuoka, K ; Rogler, G...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1288-i1289 , 2024

Link: https://doi.org/10.1093/..

14

P1013 Placebo rates in Crohn's disease: An individual patie..:

Solitano, V ; Hogan, M ; Singh, S...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1830-i1832 , 2024

Link: https://doi.org/10.1093/..

15

P857 Effectiveness and safety of subcutaneous infliximab in..:

Andre, M ; Kirchgesner, J ; Laharie, D...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1587-i1587 , 2024

Link: https://doi.org/10.1093/..